188 related articles for article (PubMed ID: 30120857)
21. Olfactory dysfunction.
Taniguchi S; Takeda A
Nihon Rinsho; 2017 Jan; 75(1):119-123. PubMed ID: 30566305
[TBL] [Abstract][Full Text] [Related]
22. Anosmia and Ageusia in Parkinson's Disease.
Tarakad A; Jankovic J
Int Rev Neurobiol; 2017; 133():541-556. PubMed ID: 28802932
[TBL] [Abstract][Full Text] [Related]
23. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
24. Prodromal Parkinson's disease and the catecholaldehyde hypothesis: Insight from olfactory bulb organotypic cultures.
Bagnoli E; Trotier A; McMahon J; Quinlan LR; Biggs M; Pandit A; FitzGerald U
FASEB J; 2023 Dec; 37(12):e23272. PubMed ID: 37997495
[TBL] [Abstract][Full Text] [Related]
25. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment.
Bang Y; Lim J; Choi HJ
Arch Pharm Res; 2021 Jun; 44(6):588-604. PubMed ID: 34145553
[TBL] [Abstract][Full Text] [Related]
27. Alpha-synuclein pathology in the olfactory pathways of dementia patients.
Hubbard PS; Esiri MM; Reading M; McShane R; Nagy Z
J Anat; 2007 Jul; 211(1):117-24. PubMed ID: 17553102
[TBL] [Abstract][Full Text] [Related]
28. Propagation of alpha-synuclein pathology from the olfactory bulb: possible role in the pathogenesis of dementia with Lewy bodies.
Cersosimo MG
Cell Tissue Res; 2018 Jul; 373(1):233-243. PubMed ID: 29196808
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical, volumetric, and functional neuroimaging studies in patients with idiopathic Parkinson's disease.
Hummel T; Witt M; Reichmann H; Welge-Luessen A; Haehner A
J Neurol Sci; 2010 Feb; 289(1-2):119-22. PubMed ID: 19775703
[TBL] [Abstract][Full Text] [Related]
30. Olfactory deficit is associated with mitral cell dysfunction in the olfactory bulb of P301S tau transgenic mice.
Li S; Li W; Wu X; Li J; Yang J; Tu C; Ye X; Ling S
Brain Res Bull; 2019 May; 148():34-45. PubMed ID: 30902575
[TBL] [Abstract][Full Text] [Related]
31. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease.
Huisman E; Uylings HB; Hoogland PV
Mov Disord; 2004 Jun; 19(6):687-92. PubMed ID: 15197709
[TBL] [Abstract][Full Text] [Related]
32. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
Athauda D; Foltynie T
Neuropharmacology; 2018 Jul; 136(Pt B):260-270. PubMed ID: 28927992
[TBL] [Abstract][Full Text] [Related]
33. The olfactory bulb volume in patients with idiopathic Parkinson's disease.
Paschen L; Schmidt N; Wolff S; Cnyrim C; van Eimeren T; Zeuner KE; Deuschl G; Witt K
Eur J Neurol; 2015 Jul; 22(7):1068-73. PubMed ID: 25912367
[TBL] [Abstract][Full Text] [Related]
34. Olfactory function combined with morphology distinguishes Parkinson's disease.
Sengoku R; Matsushima S; Bono K; Sakuta K; Yamazaki M; Miyagawa S; Komatsu T; Mitsumura H; Kono Y; Kamiyama T; Ito K; Mochio S; Iguchi Y
Parkinsonism Relat Disord; 2015 Jul; 21(7):771-7. PubMed ID: 25986741
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
36. Potential convergence of olfactory dysfunction in Parkinson's disease and COVID-19: The role of neuroinflammation.
Li H; Qian J; Wang Y; Wang J; Mi X; Qu L; Song N; Xie J
Ageing Res Rev; 2024 Jun; 97():102288. PubMed ID: 38580172
[TBL] [Abstract][Full Text] [Related]
37. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
Jia Y; Gong N; Li TF; Zhu B; Wang YX
Pharmacol Res; 2015 Dec; 102():276-85. PubMed ID: 26546042
[TBL] [Abstract][Full Text] [Related]
38. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
[TBL] [Abstract][Full Text] [Related]
39. Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra.
Joshi N; Rolheiser TM; Fisk JD; McKelvey JR; Schoffer K; Phillips G; Armstrong M; Khan MN; Leslie RA; Rusak B; Robertson HA; Good KP
J Neurol; 2017 Jul; 264(7):1497-1505. PubMed ID: 28653210
[TBL] [Abstract][Full Text] [Related]
40. alpha-Synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein- and substance P-positive cells.
Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Argandoña-Palacios L; Garcia-Muñozguren S; Martinez-Marcos A
Acta Neuropathol; 2010 Jun; 119(6):723-35. PubMed ID: 20383714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
